Lundbeck initiates two phase III studies with its main growth driver
Danish drug group Lundbeck and its Japanese partner Otsuka have started enrolling patients in two global phase III studies with the major engine of growth in the Danes’ new drugs portfolio. But neither analysts nor Lundbeck itself attach much importance to the development.
BY MARTIN HAVTORN PETERSEN
Lundbeck has initiated two new phase III studies with the major hope of the company’s new drug portfolio. This is according to a press release from Lundbeck’s US department.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Kåre Schultz: Lundbeck is in for a record year
For abonnenter
Lundbeck sees promising phase III data on Alzheimer drug
For abonnenter
Lundbeck and Otsuka win new approval for key product
For abonnenter
